<p>Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its pilot study using the Alpha DaRT® technology for recurrent glioblastoma multiforme (GBM) at The James Cancer Hospital at The Ohio State University. This marks the first time Alpha DaRT® has been used to treat brain cancer. The study is part of Alpha Tau’s broader strategy to address unmet needs in cancer treatment, particularly for GBM, which has a poor prognosis and limited treatment options. The results of this study have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598920-en) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

DRTS

<p>Alpha Tau Medical Ltd. successfully treated the first glioblastoma patient using Alpha DaRT technology in a U.S. trial at The James Cancer Hospital. This marks the first use of Alpha DaRT for brain cancer, part of Alpha Tau's strategy to address unmet cancer treatment needs. Results are pending.</p>

Alpha Tau Medical Treats First Glioblastoma Patient with Alpha DaRT in U.S. Trial